Compared with Current and Emerging Non-Insulin Therapies, Does Metformin’s Clinical Profile Justify Its Dominant Position in Recommended Treatment Guidelines? Affecting 30 million people in the…
LaunchTrends®: Lemtrada (US) is a four-wave syndicated report series that specifically tracks the introduction of Genzyme’s Lemtrada (alemtuzumab), a potent, intravenous disease-modifying…
Pulmonary arterial hypertension (PAH) is a severe and debilitating disease with rapid progression and high rates of mortality. If left untreated, life expectancy is less than three years; even…
Amid Effective TNF-α Inhibitors, What Clinical Improvements Do Rheumatologists and Payers Expect from Emerging Therapies with a Different Mechanism of Action? Axial spondyloarthritis (Ax SpA) is…
How Will New Market Entrants Fare in the Rapidly Evolving Treatment Landscape? Affecting at least 170 million people worldwide, chronic hepatitis C virus (HCV) infections are a serious public…
Physician and Payer Perspectives on Prescribing and Patient Access China has long wrestled with an increasing prevalence in respiratory diseases that has accompanied its economic growth and…
Are new drug classes expected to address the considerable unmet need? Crohn’s disease (CD) is a chronic gastrointestinal inflammatory disorder affecting over 1 million people in the major…
What Advantages Do Surveyed Oncologists and Payers Believe Emerging Therapies Must Offer to Gain Traction in This Market? The introduction of the HER2-targeting agent trastuzumab (Roche/Genentech/…
Idiopathic pulmonary fibrosis (IPF), although a rare disease, is one of the most common interstitial lung diseases (ILDs) and is characterized by irreversible loss of lung function leading to high…
A Survey of Noninterventional Cardiologists, Endocrinologists, and Managed Care Organization Pharmacy and Medical Directors The primary goal of therapy for individuals with dyslipidemia is to…
What Improvements Do Physicians and Payers Expect from Emerging Therapies? Owing to a lack of specific symptoms, the majority of patients with ovarian cancer (CaO) present at an advanced stage of…
What Attributes Will Distinguish Emerging Therapies, According to Physicians and Payers? Targeted therapies, particularly tyrosine kinase inhibitors (TKIs) that target angiogenesis, dominate the…
Can Targeting Patient Subpopulations Serve as a Market Access Lever? The asthma market is dominated by a number of effective and well-established treatments, including inhaled and oral therapies,…
How Receptive Are Ophthalmologists and U.S. Payers to Emerging Therapies in This Underserved Market? Affecting more than 40 million people in its severe form, dry eye disease represents a large,…
This quarterly report series covers the management of dialysis and mid- to late-stage chronic kidney disease (CKD) patients from the perspective of nephrologists. Emphasis is on renal anemia…